Replies to post #194316 on Biotech Values

[RNsidersbuying]

IMUC .41 - receives $19.9M grant from California Institute for Regenerative Medicine (CIRM)...to support the ICT-107 phase 3 registration trial in patients with newly diagnosed glioblastoma:

http://www.marketwatch.com/story/immunocellular-therapeutics-awarded-199-million-grant-from-california-institute-for-regenerative-medicine-cirm-to-fund-ict-107-phase-3-registration-program-in-glioblastoma-2015-09-24?siteid=bigcharts&dist=bigcharts

With .30 cash on the books now, I figure this adds another .22 in cash therefore it's now trading below cash with a phase3 in progress and backing of a governmental agency.

Bought .41's with bids below.